This retrospective study aimed to identify the frequency of HBV
reactivation and the predictive factors in patients with resolved HBV
infection who were treated with a chemotherapy regime containing rituximab for B-cell lymphoma.
In hosting districts the environmental and social conditions in which IDPs have to live are highly conducive to the acquisition and transmission of infectious diseases.15 IDPs are allowed to avail public health facilities, provided both at camp sites and in the hosting districts, but they sometimes face the social trauma of discrimination when they have to visit hospitals located in cities for complicated cases.16 The present study, the first of its kind, was planned to investigate the prevalence and transmission risks of HBV
and HCV infections among IDPs.
Because chronic hepatitis C virus infection tends to suppress HBV
replication, peginterferon/ribavirin or direct-acting anti-HCV treatment can reactivate HBV
infection, especially in patients who test positive for hepatitis B surface antigen (HBsAg).
Patients with infections of HBV
or any other virus (e.g., hepatitis virus A, C, D, E, and I) or liver diseases (e.g., hepatic cyst and hepatic metastasis) were excluded from analysis.
Core inhibitors, also known as capsid assembly modulators or core protein allosteric modulators, are a novel class of replication inhibitors that have been shown to act at multiple steps in the HBV
infection is associated with impaired virus-specific T-cell responses.
With the improvement of HBV
treatment in the last two decades and the development of new treatments against HCV, an update of data in large cohorts of kidney transplant recipients with long-term follow-up was warranted, explained lead investigator Philippe Mathurin, MD, PhD, CHRU de Lille, Chief, Service des maladies de lappareil digestif, Universit Lille 2 and Inserm U795, Lille, France.
PREVALENCEUnlike measles, flu or meningitis, whose outbreaks cause deaths within days, those infected with HBV
rarely show signs and end up without appropriate treatment.
recurrence was evaluated as the positivity of HBsAg with/without detectable serum HB-VDNA.
Recent studies have demonstrated that NCC is an efficient inhibitor of wild-type HBV
in HepG2.2.15 and HepG.CW cells.
Geographical distribution of HBV
genotypes in Africa
infection in IT phase was diagnosed as HBsAg positive more than 6 months, HBeAg positive, HBV-DNA >107 U/ml, persistent normal ALT level (<40 U/L), or mild inflammation and fibrosis in histological examination; CHB was diagnosed as HBsAg positive more than 6 months, HBeAg positive, ALT abnormal (>200 U/L) for more than 3 months, or obvious inflammation in liver by histological examination; Healthy individuals were subjects with negative for HBV
biomarkers, and ALT normal (<40 U/L).